PARIS--(BUSINESS WIRE)--Lysogene, a leading, gene therapy clinical-stage biotechnology company, today announced that it is the winner of the Deloitte In Extenso Technology Fast 50 “Biotech of the Future” Award for the Paris, France Region.
“A real measure of market value for investors, this award demonstrates French companies’ dynamism and capacity for innovation. We are convinced that these technological companies are springboards for the future, acting as catalysts to add value, dynamic growth and job creation to the French economy”
“We are thrilled to receive this prestigious award that is the result of a real commitment from our investors as well as our highly qualified and dedicated team,” said Karen Aiach, Founder and Chief Executive Officer of Lysogene.
Founded in 1995 in San Jose, California, and then extended to more than 40 countries, every year the Technology Fast 50 program promotes and recognizes companies that combine technological innovation and fast growth. It also seeks to reward companies that have demonstrated cutting edge business strategies, vision and solid management.
“A real measure of market value for investors, this award demonstrates French companies’ dynamism and capacity for innovation. We are convinced that these technological companies are springboards for the future, acting as catalysts to add value, dynamic growth and job creation to the French economy,” added Laurent Halfon, Partner in charge of Technology Fast 50, Deloitte.
About Lysogene
Lysogene is a clinical stage biotechnology company pioneering in the basic research and clinical development of AAV gene therapy for CNS disorders with a high unmet medical need. Since 2009, Lysogene has established a unique platform and network, with lead products in Sanfilippo A and GM1 Gangliosidosis, to become a global leader in orphan CNS diseases.
For more information www.lysogene.com.
Contacts
Rooney & Associates
Marion Janic, +1-212-223-4017
mjanic@rooneyco.com
